Drug shortage
Dopamine Hydrochloride Injection · Hospira, Inc., a Pfizer Company
FDA drug shortage · Current · updated Sep 22, 2026
Key facts
| Generic name | Dopamine Hydrochloride Injection |
|---|---|
| Company | Hospira, Inc., a Pfizer Company |
| Presentation | Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01) |
| Dosage form | Injection |
| Status | Current |
| Therapeutic category | Cardiovascular |
| Package NDCs | 0409-5820-01 |
| First posted | Nov 6, 2017 |
| Last updated | Sep 22, 2026 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: